WO2003077953A3 - Bacteriophage composition - Google Patents

Bacteriophage composition Download PDF

Info

Publication number
WO2003077953A3
WO2003077953A3 PCT/GB2003/001035 GB0301035W WO03077953A3 WO 2003077953 A3 WO2003077953 A3 WO 2003077953A3 GB 0301035 W GB0301035 W GB 0301035W WO 03077953 A3 WO03077953 A3 WO 03077953A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
cationic
present
peptide
delivery
Prior art date
Application number
PCT/GB2003/001035
Other languages
French (fr)
Other versions
WO2003077953A2 (en
Inventor
David West
Vladimir Di Pasechnik
Original Assignee
Phage Genomics Inc
David West
Polyanskaya Natasha Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phage Genomics Inc, David West, Polyanskaya Natasha Hf filed Critical Phage Genomics Inc
Priority to AU2003209495A priority Critical patent/AU2003209495A1/en
Publication of WO2003077953A2 publication Critical patent/WO2003077953A2/en
Publication of WO2003077953A3 publication Critical patent/WO2003077953A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The present invention provides a composition which comprises a complex of a bacteriophage and a cationic delivery moiety, such as a cationic polymer, in particular a cationic peptoid or a cationic peptide. More specifically, the present invention provides a composition comprising a complex of a bacteriophage and a delivery peptide or a protective or stabilising peptide. The present invention further provides a method for the delivery of bacteriophage across a membrane, such as a cell membrane; and a method for the treatment of bacterial infection, in particular intracellular bacterial infection, using a complex according to the invention.
PCT/GB2003/001035 2002-03-12 2003-03-12 Bacteriophage composition WO2003077953A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003209495A AU2003209495A1 (en) 2002-03-12 2003-03-12 Bacteriophage composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0205786.7 2002-03-12
GBGB0205786.7A GB0205786D0 (en) 2002-03-12 2002-03-12 Novel Composition

Publications (2)

Publication Number Publication Date
WO2003077953A2 WO2003077953A2 (en) 2003-09-25
WO2003077953A3 true WO2003077953A3 (en) 2004-01-08

Family

ID=9932799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001035 WO2003077953A2 (en) 2002-03-12 2003-03-12 Bacteriophage composition

Country Status (3)

Country Link
AU (1) AU2003209495A1 (en)
GB (1) GB0205786D0 (en)
WO (1) WO2003077953A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
GB201308742D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN115120737A (en) * 2022-04-28 2022-09-30 上海交通大学 Cationic polymer modified phage, preparation method, application and biological medicine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024959A1 (en) * 1993-04-27 1994-11-10 Symbiotech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
US5688501A (en) * 1994-04-05 1997-11-18 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1999010014A2 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
WO2000061190A2 (en) * 1999-04-09 2000-10-19 Microbiological Research Authority Treatment of intracellular infection
WO2001037807A1 (en) * 1999-11-24 2001-05-31 The Liposome Company, Inc. Modular targeted liposomal delivery system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1994024959A1 (en) * 1993-04-27 1994-11-10 Symbiotech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
US5688501A (en) * 1994-04-05 1997-11-18 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system
WO1999010014A2 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
WO2000061190A2 (en) * 1999-04-09 2000-10-19 Microbiological Research Authority Treatment of intracellular infection
WO2001037807A1 (en) * 1999-11-24 2001-05-31 The Liposome Company, Inc. Modular targeted liposomal delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POOGA M ET AL: "Cell penetration by transportan.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES JAN 1998, vol. 12, no. 1, January 1998 (1998-01-01), pages 67 - 77, XP002219568, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
GB0205786D0 (en) 2002-04-24
WO2003077953A2 (en) 2003-09-25
AU2003209495A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2002057664A3 (en) Bacillus thuringiensis insecticidal proteins
AU2525401A (en) Use of an extract of at least one vaccinium-type plant as an anti-glycation agent
WO2003093441A3 (en) A method of regulating gene expression
CA2523467C (en) Treatment of t-cell mediated diseases
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2008041966A3 (en) Broad spectrum antibacterial compounds
WO2003015809A3 (en) Antimicrobial cationic peptides and formulations thereof
EP1300468A3 (en) TRNA synthetase
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
WO2006128089A3 (en) Compositions and methods for treating tissue
WO2001092309A3 (en) Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
WO2003063851A8 (en) Composition for pharmaceutical or dietetic use for combating hair loss
WO2004082366A3 (en) Methods to confer enhanced floral properties to plants
AU2003222717A1 (en) Streptavidin-binding peptide
MX2007011381A (en) Spirulin composition rich in active principles, method for obtaining same and use thereof.
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
WO2003077953A3 (en) Bacteriophage composition
WO2006109192A8 (en) Antifungal bifunctional molecules, methods of construction and methods of treating fungal infection therewith
AU3163100A (en) Benzofuran-2-one
WO2004000207A3 (en) Toxin-phage bacteriocide antibiotic and uses thereof
WO2003106640A3 (en) Cell targeting methods and compositions
WO2003035889A3 (en) Compositions and methods for bacteria detection
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP